The specific pathway of tropoelastin secretion was investigated in fetal calf ligamentum nuchae (FCL) cells using brefeldin A (BFA) to disrupt the secretory pathway. Electron microscopic studies of BFA-treated FCL cells showed ultrastructural changes consistent with the reported effects of BFA on intracellular organelles. When FCL cells were labeled with [H]leucine in the presence of BFA, radiolabeled tropoelastin was not secreted, nor was there an intracellular accumulation of the protein. In contrast, fibronectin accumulated within the cells in the presence of BFA. Northern analysis of mRNA levels in FCL cells showed that the message for tropoelastin was unaffected by BFA treatment. Pulse chase experiments conducted in the presence of BFA demonstrated that the tropoelastin retained within the cells was rapidly degraded. Ammonium chloride, nocodazole, and cycloheximide had no effect on the degradation of tropoelastin, indicating that the degradation did not involve the endosome/lysosome pathway, movement via microtubules, or a short-lived protein, respectively. Incubation of FCL cells with BFA in the presence of N-acetyl-Leu-Leu-norleucinal, however, allowed tropoelastin to steadily accumulate in the cells. Cells pulsed in the presence of BFA alone showed that tropoelastin initially accumulates within the cells for approximately 1 h prior to being degraded, thus indicating that a critical threshold of tropoelastin must be reached before degradation can occur. Results from this study provide evidence for selective degradation of a soluble secreted protein by a cysteine protease following retention of the protein in the endoplasmic reticulum.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. M. Kelleher, E. K. Silverman, T. Broekelmann, A. A. Litonjua, M. Hernandez, J. S. Sylvia, J. Stoler, J. J. Reilly, H. A. Chapman, F. E. Speizer, et al. A Functional Mutation in the Terminal Exon of Elastin in Severe, Early-Onset Chronic Obstructive Pulmonary Disease Am. J. Respir. Cell Mol. Biol., October 1, 2005; 33(4): 355 - 362. [Abstract] [Full Text] [PDF]

				C. E. Patterson, T. Schaub, E. J. Coleman, and E. C. Davis Developmental Regulation of FKBP65. An ER-localized Extracellular Matrix Binding-Protein Mol. Biol. Cell, November 1, 2000; 11(11): 3925 - 3935. [Abstract] [Full Text]

				B. W. Robb, H. Wachi, T. Schaub, R. P. Mecham, and E. C. Davis Characterization of an In Vitro Model of Elastic Fiber Assembly Mol. Biol. Cell, November 1, 1999; 10(11): 3595 - 3605. [Abstract] [Full Text]

				E. C. Davis, T. J. Broekelmann, Y. Ozawa, and R. P. Mecham Identification of Tropoelastin as a Ligand for the 65-kD FK506-binding Protein, FKBP65, in the Secretory Pathway J. Cell Biol., January 26, 1998; 140(2): 295 - 303. [Abstract] [Full Text] [PDF]

				R. Halaban, E. Cheng, Y. Zhang, G. Moellmann, D. Hanlon, M. Michalak, V. Setaluri, and D. N. Hebert Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells PNAS, June 10, 1997; 94(12): 6210 - 6215. [Abstract] [Full Text] [PDF]